10 February 2016
: Case report
Pulmonary Nocardiosis in a Multiple Myeloma Patient Treated with Proteasome Inhibitors
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Adverse events of drug therapy , Educational Purpose (only if useful for a systematic review or synthesis), Rare coexistence of disease or pathology
Nikolai P. MendoncaEF, Deepak K. KadayakkaraEF, Inga C. FordeE, Anastasiia Rudkovskaia, Zane K. SaulE, David J. LoboEFDOI: 10.12659/AJCR.896280
Am J Case Rep 2016; 17:76-78
Abstract
BACKGROUND: The use of proteasome inhibitors like Bortezomib to treat multiple myeloma has been associated with increased rates of opportunistic infections, including Nocardia, especially when lymphopenia is present. The prevalence or association of such infections with newer agents like Carfilzomib is not known.
CASE REPORT: A 71-year-old man with multiple myeloma presented with a 6-week history of respiratory symptoms and cyclic fevers. He was undergoing chemotherapy with Carfilzomib. Work-up revealed severe lymphopenia and a CT chest showed multiple lung nodules and a mass-like consolidation. He underwent a bronchoscopy, and respiratory cultures grew Nocardia species. He responded well to intravenous antibiotics with resolution of symptoms and CT findings.
CONCLUSIONS: With the introduction of newer agents like Carfilzomib for the treatment of multiple myeloma, clinicians must maintain a high degree of suspicion for opportunistic infections to achieve early diagnosis and treatment.
Keywords: Immunocompromised Host, Multiple Myeloma - drug therapy, Nocardia Infections - diagnosis, Oligopeptides - therapeutic use, Opportunistic Infections - diagnosis, Proteasome Inhibitors - therapeutic use
In Press
26 Jan 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938169
26 Jan 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939026
26 Jan 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938982
26 Jan 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938850
Most Viewed Current Articles
13 Jul 2022 : Case report
DOI :10.12659/AJCR.936441
Am J Case Rep 2022; 23:e936441
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
17 Feb 2022 : Case report
DOI :10.12659/AJCR.934399
Am J Case Rep 2022; 23:e934399